Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

[Physiotherapy for young patients suffering from malignant bone tumors].

Bové B, Triantafyllou C, Duché A, Sanzey C, Aristide C, Mejane C, Ansinelli JM.

Soins Pediatr Pueric. 2013 Jan-Feb;(270):26-8. French.

PMID:
23379066
2.

Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.

Brewster BL, Rossiello F, French JD, Edwards SL, Wong M, Wronski A, Whiley P, Waddell N, Chen X, Bove B; kConFab, Hopper JL, John EM, Andrulis I, Daly M, Volorio S, Bernard L, Peissel B, Manoukian S, Barile M, Pizzamiglio S, Verderio P, Spurdle AB, Radice P, Godwin AK, Southey MC, Brown MA, Peterlongo P.

Hum Mutat. 2012 Dec;33(12):1665-75. doi: 10.1002/humu.22159. Epub 2012 Aug 2.

PMID:
22753153
3.

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.

Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H; OCGN, Thomassen M, Paligo M, Aretini P; SWE-BRCA, Kantala J, Aroer B, von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M, Benítez J, Gilbert M; HEBON, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AM, Seynaeve C, van der Luijt RB, Devilee P; EMBRACE, Easton DF, Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B; GEMO Study Collaborators, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson OT, Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P, Durocher F, Chenevix-Trench G, Beesley J, Chen X; KConFab, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J; CIMBA, the Consortium of Investigators of Modifiers of BRCA1/2-Related Cancer.

Br J Cancer. 2012 Jun 5;106(12):2016-24. doi: 10.1038/bjc.2012.160. Epub 2012 May 15.

4.

Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL; OCGN, Ozcelik H, Mulligan AM, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P; SWE-BRCA, Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Górski B, Osorio A, Durán M, Tejada MI, Benitez J, Hamann U, Hogervorst FB; HEBON, van Os TA, van Leeuwen FE, Meijers-Heijboer HE, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems MG, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE; EMBRACE, Bove B, Godwin AK, Stoppa-Lyonnet D; GEMO Study Collaborators, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry M, Chung WK, John EM, Miron A, Southey MC, Hopper JL, Goldgar DE, Singer CF, Rappaport C, Tea MK, Fink-Retter A, Hansen TV, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson ME, Piedmonte M, Phillips K, Basil J, Rubinstein WS, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PP, Odunsi KO, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz MD, Spurdle AB, Neuhausen SL, Ding YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G; kConFab investigators, Offit K, Simard J; Consortium of Investigators of Modifiers of BRCA1/2.

Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.

5.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.

Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, Loman N, Harbst K, Lindblom A, Arver B, Rosenquist R, Karlsson P, Nathanson K, Domchek S, Rebbeck T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowowcka-Perłowska E, Osorio A, Durán M, Andrés R, Benítez J, Hamann U, Hogervorst FB, van Os TA, Verhoef S, Meijers-Heijboer HE, Wijnen J, Gómez Garcia EB, Ligtenberg MJ, Kriege M, Collée JM, Ausems MG, Oosterwijk JC, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Rogers MT, Donaldson A, Dorkins H, Godwin AK, Bove B, Stoppa-Lyonnet D, Houdayer C, Buecher B, de Pauw A, Mazoyer S, Calender A, Léoné M, Bressac-de Paillerets B, Caron O, Sobol H, Frenay M, Prieur F, Ferrer SU, Mortemousque I, Buys S, Daly M, Miron A, Terry MU, Hopper JL, John EM, Southey M, Goldgar D, Singer CF, Fink-Retter A, Tea MK, Kaulich DU, Hansen TV, Nielsen FC, Barkardottir RB, Gaudet M, Kirchhoff T, Joseph V, Dutra-Clarke A, Offit K, Piedmonte M, Kirk J, Cohn D, Hurteau J, Byron J, Fiorica J, Toland AE, Montagna M, Oliani C, Imyanitov E, Isaacs C, Tihomirova L, Blanco I, Lazaro C, Teulé A, Valle JD, Gayther SA, Odunsi K, Gross J, Karlan BY, Olah E, Teo SH, Ganz PA, Beattie MS, Dorfling CM, van Rensburg EU, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schäfer D, Caldes T, de la Hoya M, Nevanlinna H, Muranen TA, Lespérance B, Spurdle AB, Neuhausen SL, Ding YC, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Loud JT, Andrulis IL, Ozcelik H, Mulligan AU, Glendon G, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Chenevix-Trench G, Couch FJ, Simard J, Easton DF; CIMBA, SWE-BRCA; HEBON; EMBRACE; GEMO Collaborators Study; kConFab Investigators.

Breast Cancer Res. 2012 Feb 20;14(1):R33.

6.

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer.

Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ.

Br J Cancer. 2012 Feb 14;106(4):748-55. doi: 10.1038/bjc.2011.587. Epub 2012 Jan 12.

7.

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.

Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, von Mehren M.

Cancer Chemother Pharmacol. 2012 Apr;69(4):977-82. doi: 10.1007/s00280-011-1785-7. Epub 2011 Nov 27.

8.

Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.

Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG.

Cancer Prev Res (Phila). 2010 Jan;3(1):48-61. doi: 10.1158/1940-6207.CAPR-09-0078.

9.

Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia.

Fang CY, Miller SM, Bovbjerg DH, Bergman C, Edelson MI, Rosenblum NG, Bove BA, Godwin AK, Campbell DE, Douglas SD.

Ann Behav Med. 2008 Feb;35(1):87-96. doi: 10.1007/s12160-007-9007-6. Epub 2008 Feb 13.

10.

Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.

Chen X, Weaver J, Bove BA, Vanderveer LA, Weil SC, Miron A, Daly MB, Godwin AK.

Hum Mol Genet. 2008 May 1;17(9):1336-48. doi: 10.1093/hmg/ddn022. Epub 2008 Jan 19.

PMID:
18204050
11.

[SOR SAVOIR PATIENT Cancer and fatigue. Information dedicated to cancer patients and relatives].

Dielenseger P, Dilhuydy JM, Brusco S, Chazot L, Blay JY, Bové B, Colcanap B, Ferrandez JC, Floquet A, Jane Gledhill, Hubert N, Meslier M, Rosman S, Carretier J, Delavigne V, Fervers B, Leichtnam-Dugarin L, Philip T; Standards, Options et Recommandations (SOR); Ligue Nationale contre le Cancer; Institut National du Cancer; Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC); A. F. I. C; Vie en Couleurs; Fédération Hospitalière de France; Fédération Nationale de Cancérologie des Centres Hospitaliers Régionaux et Universitaires (FNCHRU); Fédération Française de Cancérologie (CHG).

Bull Cancer. 2006 Dec;93(12):1213-27. French.

12.

Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.

Chen X, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK.

Hum Mutat. 2006 May;27(5):427-35.

PMID:
16619214
13.

Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred.

Prowse AH, Schultz DC, Guo S, Vanderveer L, Dangel J, Bove B, Cairns P, Daly M, Godwin AK.

J Med Genet. 2003 Aug;40(8):e102. No abstract available.

14.

Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.

Wagner Costalas J, Itzen M, Malick J, Babb JS, Bove B, Godwin AK, Daly MB.

Am J Med Genet C Semin Med Genet. 2003 May 15;119C(1):11-8.

PMID:
12704633
15.

Demolition of a hospital building by controlled explosion: the impact on filamentous fungal load in internal and external air.

Bouza E, Peláez T, Pérez-Molina J, Marín M, Alcalá L, Padilla B, Muñoz P, Adán P, Bové B, Bueno MJ, Grande F, Puente D, Rodríguez MP, Rodríguez-Créixems M, Vigil D, Cuevas O; Aspergillus Study Team.

J Hosp Infect. 2002 Dec;52(4):234-42.

PMID:
12473466
16.

DNA array-based method for detection of large rearrangements in the BRCA1 gene.

Frolov A, Prowse AH, Vanderveer L, Bove B, Wu H, Godwin AK.

Genes Chromosomes Cancer. 2002 Nov;35(3):232-41.

PMID:
12353265
17.

Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations.

Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS; Cooperative Family Registry for Breast Cancer studies.

Hum Mutat. 2002 Jul;20(1):65-73.

PMID:
12112659
18.

A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.

Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP.

Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):955-60.

19.

Novel germline BRCA1 mutation (155del4) in an African American with early-onset breast cancer.

Dangel J, Wagner-Costalas J, Bove B, Vanderveer L, Itzen M, Daly M, Godwin AK.

Hum Mutat. 1999 Dec;14(6):545. No abstract available.

PMID:
10571958
20.

Allelic instability as a predictor of survival in Egyptian breast cancer patients.

Zekri AR, Bahnassi AA, Bove B, Huang Y, Russo IH, Rogatko A, Shaarawy S, Shawki OA, Hamza MR, Omer S, Khaled HM, Russo J.

Int J Oncol. 1999 Oct;15(4):757-67.

PMID:
10493959
21.

Microsatellite instability during the immortalization and transformation of human breast epithelial cells in vitro.

Huang Y, Bove B, Wu Y, Russo IH, Yang X, Zekri A, Russo J.

Mol Carcinog. 1999 Feb;24(2):118-27.

PMID:
10078939
22.

Biological and molecular basis of human breast cancer.

Russo J, Yang X, Hu YF, Bove BA, Huang Y, Silva ID, Tahin Q, Wu Y, Higgy N, Zekri A, Russo IH.

Front Biosci. 1998 Sep 1;3:D944-60. Review.

PMID:
9727085
23.

Appearance of acinar-cell-specific mucin in prenatal mouse submandibular glands.

Denny PA, Pimprapaiporn W, Bove BJ, Chai Y, Kim MS, Denny PC.

Differentiation. 1989 May;40(2):93-8.

PMID:
2759365
24.

Long survival in a 69,XXY triploid male.

Sherard J, Bean C, Bove B, DelDuca V Jr, Esterly KL, Karcsh HJ, Munshi G, Reamer JF, Suazo G, Wilmoth D, et al.

Am J Med Genet. 1986 Oct;25(2):307-12.

PMID:
3777027
25.

[Histochemical and immunohistochemical study of mixed tumors with unusual histologic aspects].

Nigro M, Facchetti F, Bove B, Marino F.

G Ital Dermatol Venereol. 1985 Sep-Oct;120(5):359-63. Italian. No abstract available.

PMID:
3000930
26.

Identification of a nitrosamino aldehyde and a nitrosamino acid resulting from beta-oxidation of N-nitrosodiethanolamine.

Airoldi L, Bonfanti M, Fanelli R, Bove B, Benfenati E, Gariboldi P.

Chem Biol Interact. 1984 Sep 1;51(1):103-13.

PMID:
6547642

Supplemental Content

Support Center